Goldman Sachs Group Inc. Grows Position in TransMedics Group, Inc. $TMDX

Goldman Sachs Group Inc. raised its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 50.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 965,931 shares of the company’s stock after purchasing an additional 322,353 shares during the quarter. Goldman Sachs Group Inc.’s holdings in TransMedics Group were worth $117,506,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. D.A. Davidson & CO. grew its holdings in TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after buying an additional 83 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after buying an additional 88 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock valued at $277,000 after buying an additional 88 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in shares of TransMedics Group by 24.2% in the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after purchasing an additional 104 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 2.5%

TMDX opened at $71.14 on Tuesday. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 16.17 and a beta of 1.92. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The stock has a fifty day moving average price of $88.16 and a 200-day moving average price of $116.65.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the firm posted $0.70 earnings per share. The company’s revenue was up 21.2% on a year-over-year basis. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of recent research reports. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Stifel Nicolaus dropped their target price on TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a report on Tuesday, May 26th. Needham & Company LLC dropped their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, TD Cowen dropped their target price on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.